血液生物标志物聚类分析识别肺纤维化分子模式:多中心前瞻性观察队列及独立验证
本研究对PROFILE队列455例肺纤维化患者进行13种血液生物标志物的无监督共识聚类,识别出基底膜胶原(BM)、上皮损伤(EI)和交联纤维蛋白(XF)三个簇,并在澳大利亚AIPFR队列中验证。EI和XF簇较BM簇死亡风险增加,EI簇年FVC%下降最显著,提示肺纤维化存在不同内型。
要点
- 肺纤维化患者可基于血液生物标志物分为BM、EI、XF三个分子簇。
- EI簇和XF簇较BM簇死亡风险增加,EI簇年FVC%下降最显著。
- 三个簇在独立AIPFR队列中可重复识别,提示内型具有可推广性。
核心结论
- 肺纤维化血液生物标志物聚类识别出三个与肺功能和预后相关的标志物特征,支持存在不同内型。
研究设计与样本
- PROFILE为英国多中心前瞻性观察队列,纳入新发特发性肺纤维化或非特异性间质性肺炎患者。
- 采用ELISA检测13种代表细胞外基质重塑、上皮应激和血栓形成的血液生物标志物。
- 采用无监督共识聚类分类,并用机器学习分类器在澳大利亚AIPFR注册队列中验证。
- PROFILE分析纳入455/580例参与者,AIPFR复制数据集纳入117/833例患者。
主要发现
- PROFILE队列识别出BM簇(n=248,55%)、EI簇(n=109,24%)和XF簇(n=98,22%)。
- AIPFR队列识别出相同三簇:BM簇(n=93,79%)、EI簇(n=8,7%)、XF簇(n=16,14%)。
- EI簇年FVC%下降最显著,其次为BM簇和XF簇,AIPFR中观察到类似下降模式。
关键数值与推荐
- BM簇特征为PRO-C4、PRO-C28、C3M和C6M浓度高。
- EI簇特征为MMP-7、SP-D、CYFRA211、CA19-9和CA-125浓度高。
- XF簇特征为X-FIB浓度高。
临床怎么用
- 血液生物标志物聚类可能有助于肺纤维化患者风险分层和预后判断。
- EI簇和XF簇死亡风险较高,或需更密切监测和积极治疗。
- 研究结果支持针对不同内型开发靶向治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pulmonary fibrosis results from alveolar injury, leading to extracellular matrix remodelling and impaired lung function. This study aimed to classify patients with pulmonary fibrosis according to blood biomarkers to differentiate distinct disease patterns, known as endotypes. METHODS: In this cluster analysis, we first classified patients from the PROFILE study, a multicentre, prospective, observational cohort of individuals with incident idiopathic pulmonary fibrosis or non-specific interstitial pneumonia in the UK (Nottingham University Hospitals, Nottingham; and Royal Brompton Hospital, London). 13 blood biomarkers representing extracellular matrix remodelling, epithelial stress, and thrombosis were measured by ELISA in the PROFILE study. We classified patients by unsupervised consensus clustering. To evaluate generalisability, a machine learning classifier trained on biomarker signatures derived from consensus clustering was applied to a replication dataset from the Australian Idiopathic Pulmonary Fibrosis Registry (AIPFR). Biomarker associations with mortality and change in percentage of predicted forced vital capacity (FVC%) were assessed, adjusting for age, gender, baseline FVC%, and antifibrotic treatment and steroid treatment before and after baseline. Mortality risk associated with the clusters in the PROFILE cohort was evaluated with Cox proportional hazards models, and mixed-effects models were used to analyse how clustering was associated with longitudinal FVC% in the PROFILE and AIPFR cohorts. FINDINGS: 455 of 580 participants from the PROFILE study (348 [76%] men and 107 [24%] women; mean age 72·4 years [SD 8·3]) were included in the analysis. Within this group, three clusters were identified based on blood biomarkers. A basement membrane collagen (BM) cluster (n=248 [55%]) showed high concentrations of PRO-C4, PRO-C28, C3M, and C6M, whereas an epithelial injury (EI) cluster (n=109 [24%]) showed high concentrations of MMP-7, SP-D, CYFRA211, CA19-9, and CA-125. The third cluster (crosslinked fibrin [XF] cluster; n=98 [22%]) had high concentrations of X-FIB. In the replication dataset (117 of 833 patients from AIPFR; 87 [74%] men and 30 [26%] women; mean age 72·9 years [SD 7·9]), we identified the same three clusters (BM cluster, n=93 [79%]; EI cluster, n=8 [7%]; XF cluster, n=16 [14%]). These clusters showed similarities with clusters in the PROFILE dataset regarding blood biomarkers and phenotypic signatures. In the PROFILE dataset, the EI and XF clusters were associated with increased mortality risk compared with the BM cluster (EI vs BM: adjusted hazard ratio [HR] 1·88 [95% CI 1·42-2·49], p<0·0001; XF vs BM: adjusted HR 1·53 [1·13-2·06], p=0·0058). The EI cluster showed the greatest annual FVC% decline, followed by the BM and XF clusters. A similar FVC% decline pattern was observed in these clusters in the AIPFR replication dataset. INTERPRETATION: Blood biomarker clustering in pulmonary fibrosis identified three distinct blood biomarker signatures associated with lung function and prognosis, suggesting unique pulmonary fibrosis biomarker patterns. These findings support the presence of pulmonary fibrosis endotypes with the potential to guide targeted therapy development. FUNDING: None.
引用
- Fainberg HP, Moodley Y, Triguero I, et al. Cluster analysis of blood biomarkers to identify molecular patterns in pulmonary fibrosis: assessment of a multicentre, prospective, observational cohort with independent validation. Lancet Respir Med. 2024. PMID: 39025091. doi:10.1016/S2213-2600(24)00147-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。